Solarvest Continues To Add Expertise To Its Cannabinoid Active Pharmaceutical Ingredient (API) Program

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

(TheNewswire)



  

Vancouver, BC – TheNewswire - September 26th, 2019 SOLARVEST BIOENERGY INC. (TSXV:SVS) (“Solarvest” or the “Company”), is pleased to announce that Dr. Azoy Kumar Kundu has joined Solarvest’s protein expression team.  His extensive background includes protein science and in-depth experience in genetic technologies.  He worked in a team that was successful in developing and receiving FDA approval for the world’s first GMO food animal.  

 

Dr. Kundu’s experience will be a significant addition to the team for the ongoing lab work for Solarvest’s collaborative program to produce API (“approved pharmaceutical ingredient”) cannabinoids utilizing our algal biopharmaceutical platform.  Azoy will specifically bring to the team his expertise in the construction of vectors, molecular cloning and DNA manipulation.  His experience with GLP, quality assurance, bioassay development, study protocol development, study design, study validation, and study report writing will be vital to ensure regulatory approval of any successful cannabinoid expressed and purified for use as an API.

 

About Solarvest:

Solarvest BioEnergy Inc. is an algae biotechnology company whose algal-based production platform provides it with an extremely flexible system capable of being adapted to produce numerous products - from Omega 3 fatty acids to human therapeutic proteins.  The company has successfully demonstrated (news release dated March 16th. 2015) the expression of BMP, a high value therapeutic protein. In addition the company’s platform has successfully produced recombinant viral antigens (immune stimulating proteins,) Cecropins (antimicrobial pepetide/protein). The company has initiated a program for the expression of CBD and THC.as a way to produce CBD and THC in sterile bioreactors.

For further information contact:  

Garth Greenham, COO Solarvest Bioenergy Inc.

Tel: 416 420 0947 Email: [email protected]

The TSX Venture Exchange has neither approved nor disapproved the contents of this news release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

The statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company’s expectations and projections.

.

Copyright (c) 2019 TheNewswire - All rights reserved.